Drug Policy

SB 2117 adds 13 specific substances - including multiple fentanyl variants like acetyl fentanyl, beta-methyl fentanyl, and others - to Mississippi's Schedule I controlled substances list. It also creates a broad category covering fentanyl-related substances with structural modifications (e.g., changes to the phenethyl group or piperidine ring). This classification means these substances are deemed to have no legitimate medical use and a high potential for harm under Mississippi law. The bill directly affects anyone possessing, distributing, or using these substances within Mississippi, subjecting them to stricter state penalties.

SB 2056 automatically adds to Mississippi's controlled substances schedules any psilocybin-based pharmaceutical product approved by the U.S. Food and Drug Administration (FDA) and scheduled by the U.S. Drug Enforcement Administration (DEA). This applies directly to pharmaceutical companies developing such products and state law enforcement handling them under existing penalties. The bill requires the state to mirror federal scheduling immediately upon federal action, with the automatic status lasting until the next legislative session or until state law is amended. It also updates Section 41-29-111 to remove outdated references to pandemic-related provisions. The bill does not change Mississippi's scheduling process for substances not federally scheduled.

This bill (HB 13) adds kratom to Schedule III of Mississippi's controlled substances list, classifying it as a regulated substance with potential for abuse. It directly affects anyone possessing, distributing, or using kratom within Mississippi, as it would now require a prescription and be subject to state drug laws. The key mechanism is amending Section 41-29-117 of the Mississippi Code to explicitly include kratom under Schedule III, which governs substances with accepted medical use but abuse potential. This changes kratom's legal status from unregulated to controlled under state law.

HB 865 would reclassify kratom as a Schedule III controlled substance under Mississippi's Uniform Controlled Substances Law, removing it from its current unregulated status. This change would allow kratom to be prescribed by doctors for medical use (as Schedule III substances have accepted medical uses) while still requiring prescriptions and regulating its distribution. The bill directly affects Mississippi residents who use kratom, pharmacies dispensing it, and law enforcement handling related cases. Note: The bill title incorrectly references marijuana; this bill specifically addresses kratom, not cannabis.

HB 448 amends Mississippi's Uniform Controlled Substances Law to remove hypodermic syringes from the legal definition of "paraphernalia." This means possessing or using a hypodermic syringe for legitimate medical purposes, such as insulin injections for diabetes, will no longer be considered a violation under paraphernalia laws. The bill directly affects medical patients who rely on syringes and healthcare providers who administer medications via syringes. It does not change laws regarding drug possession or use, only clarifies that syringes themselves are not subject to paraphernalia penalties.